Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artivion, Inc. stock logo
AORT
Artivion
$28.21
-1.8%
$26.46
$21.97
$32.33
$1.20B1.62334,936 shs242,570 shs
DNAA
Social Capital Suvretta Holdings Corp. I
$14.07
$11.74
$9.07
$17.44
$360.76M-0.02182,488 shs4.63 million shs
Paragon 28, Inc. stock logo
FNA
Paragon 28
$13.11
+0.1%
$13.09
$4.65
$13.13
$1.10B1.471.13 million shs19.38 million shs
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$20.76
-0.8%
$19.94
$15.75
$48.24
$1.38B1.521.50 million shs1.12 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artivion, Inc. stock logo
AORT
Artivion
-1.84%-2.66%-2.46%+16.84%+19.64%
DNAA
Social Capital Suvretta Holdings Corp. I
0.00%0.00%0.00%0.00%0.00%
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.00%0.00%0.00%+0.61%+99.16%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-0.76%-0.10%-9.15%+8.29%-56.16%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Artivion, Inc. stock logo
AORT
Artivion
3.4845 of 5 stars
2.65.00.00.03.02.51.9
DNAA
Social Capital Suvretta Holdings Corp. I
N/AN/AN/AN/AN/AN/AN/AN/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/AN/AN/AN/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
4.0907 of 5 stars
4.21.00.04.92.80.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artivion, Inc. stock logo
AORT
Artivion
3.17
Buy$31.4011.31% Upside
DNAA
Social Capital Suvretta Holdings Corp. I
0.00
N/AN/AN/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
2.20
Hold$12.75-2.71% Downside
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.43
Hold$34.1564.52% Upside

Current Analyst Ratings Breakdown

Latest DNAA, TNDM, AORT, and FNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$20.00 ➝ $24.00
5/6/2025
Artivion, Inc. stock logo
AORT
Artivion
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/6/2025
Artivion, Inc. stock logo
AORT
Artivion
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$33.00 ➝ $33.00
5/6/2025
Artivion, Inc. stock logo
AORT
Artivion
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
5/1/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$58.00 ➝ $59.00
5/1/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$60.00 ➝ $31.00
5/1/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$22.00 ➝ $20.00
5/1/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$36.00 ➝ $30.00
5/1/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$33.00 ➝ $24.00
4/10/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$20.00
4/9/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artivion, Inc. stock logo
AORT
Artivion
$390.08M3.09$0.77 per share36.78$6.87 per share4.11
DNAA
Social Capital Suvretta Holdings Corp. I
N/AN/AN/AN/A($0.33) per shareN/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
$256.18M4.29N/AN/A$2.05 per share6.39
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$982.95M1.41N/AN/A$4.81 per share4.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artivion, Inc. stock logo
AORT
Artivion
-$30.69M-$0.50N/A56.42N/A-0.22%5.15%1.91%8/6/2025 (Estimated)
DNAA
Social Capital Suvretta Holdings Corp. I
-$2.44MN/A0.00N/AN/AN/A-3.32%N/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$57.53M-$0.63N/AN/AN/A-25.31%-37.90%-18.22%N/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$222.61M-$2.78N/AN/AN/A-14.84%-44.19%-11.99%7/30/2025 (Estimated)

Latest DNAA, TNDM, AORT, and FNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2025Q1 2025
Artivion, Inc. stock logo
AORT
Artivion
$0.12$0.06-$0.06-$0.01$94.81 million$98.98 million
4/30/2025Q1 2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$0.60-$0.67-$0.07-$1.97$220.19 million$234.42 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Artivion, Inc. stock logo
AORT
Artivion
N/AN/AN/AN/AN/A
DNAA
Social Capital Suvretta Holdings Corp. I
N/AN/AN/AN/AN/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artivion, Inc. stock logo
AORT
Artivion
0.71
1.88
1.33
DNAA
Social Capital Suvretta Holdings Corp. I
N/A
0.09
0.09
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.79
3.50
1.60
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
1.29
2.90
2.32

Institutional Ownership

CompanyInstitutional Ownership
Artivion, Inc. stock logo
AORT
Artivion
86.37%
DNAA
Social Capital Suvretta Holdings Corp. I
N/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
63.57%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Artivion, Inc. stock logo
AORT
Artivion
1,30042.70 million38.52 millionOptionable
DNAA
Social Capital Suvretta Holdings Corp. I
425.64 millionN/ANot Optionable
Paragon 28, Inc. stock logo
FNA
Paragon 28
343,00083.94 million70.89 millionOptionable
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2,60066.61 million64.23 millionOptionable

Recent News About These Companies

Tandem agrees to pay $36M to settle Roche patent litigation

New MarketBeat Followers Over Time

Media Sentiment Over Time

Artivion stock logo

Artivion NYSE:AORT

$28.21 -0.53 (-1.84%)
Closing price 06/13/2025 03:59 PM Eastern
Extended Trading
$28.24 +0.03 (+0.11%)
As of 06/13/2025 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Social Capital Suvretta Holdings Corp. I NASDAQ:DNAA

Social Capital Suvretta Holdings Corp. I does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the biotechnology industry. The company was incorporated in 2021 and is based in Henderson, Nevada.

Paragon 28 stock logo

Paragon 28 NYSE:FNA

$13.10 +0.02 (+0.11%)
Closing price 04/17/2025
Extended Trading
$13.10 0.00 (0.00%)
As of 04/17/2025 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

Tandem Diabetes Care stock logo

Tandem Diabetes Care NASDAQ:TNDM

$20.76 -0.16 (-0.76%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$20.77 +0.01 (+0.05%)
As of 06/13/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.